RE: 2012 Fourth Quarter and Year-End Financial Res These are all of Medicago's accomplishments for 2012. How much did they equate to in share price? Almost nothing?
In which year (can anybody guess) will it be that MDG actually does something that will be accretive to the bottom line and the constant loss scenario will turn to profit i.e. will they ever have a product to sell and ,if so, when? I know, these drug companies take forever, so one just has to be very patient. I'm just not sure I started young enough.
"2012 was a significant year for Medicago as we completed multiple strategic agreements for our plant-based vaccines. We have been successful in attracting major players and are now opening doors to new global opportunities," said Andy Sheldon, President and CEO of Medicago. "These include a strategic alliance with Mitsubishi Tanabe which includes $33 million in upfront and milestone payments, our first commercial license agreement for influenza vaccines in China with Philip Morris Products, as well as the successful completion of a $21 million project with U.S. Department of Defense for the production of significantly more than 10 million doses of H1N1 influenza VLP vaccine at our commercial-scale facility in North Carolina. In addition, we completed a research collaboration agreement with a top 10 pharmaceutical company, a collaboration with Mitsubishi Chemical Corporation and recently signed a $15 million non-dilutive loan with a major pharmaceutical company with whom we are continuing discussions to finalize a licensing agreement which may also include co-promotion rights of Medicago vaccines in certain markets and, if successfully concluded will result in the principal of the loan being applied as upfront payments upon the execution of the licensing agreement."